AstraZeneca secures $400 million deal for heart failure treatment commercial rights
AstraZeneca tidied up its portfolio of drugs today with a US$400 million deal selling commercial rights to its medicine for heart failure and hypertension.
AstraZeneca tidied up its portfolio of drugs today with a US$400 million deal selling commercial rights to its medicine for heart failure and hypertension.